The FDA, in co-sponsorship with the FNIH Biomarkers Consortium, hosted a public meeting in April titled “Developing an Evidentiary Criteria Framework for Safety Biomarkers Qualification”.
Dr. Dennis Black discusses the significance of the Bone Quality Project’s first study results in a recent Q & A.
The Biomarkers Consortium is a public private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
The Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.